Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts.
Journal
Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R
Informations de publication
Date de publication:
01 Sep 2019
01 Sep 2019
Historique:
received:
31
01
2019
revised:
16
04
2019
accepted:
23
05
2019
pubmed:
31
5
2019
medline:
26
9
2019
entrez:
31
5
2019
Statut:
ppublish
Résumé
Identifying robust biomarkers of drug response constitutes a key challenge in precision medicine. Patient-derived tumor xenografts (PDX) have emerged as reliable preclinical models that more accurately recapitulate tumor response to chemo- and targeted therapies. However, the lack of computational tools makes it difficult to analyze high-throughput molecular and pharmacologic profiles of PDX. We have developed Xenograft Visualization & Analysis (Xeva), an open-source software package for
Identifiants
pubmed: 31142512
pii: 0008-5472.CAN-19-0349
doi: 10.1158/0008-5472.CAN-19-0349
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4539-4550Commentaires et corrections
Type : CommentIn
Informations de copyright
©2019 American Association for Cancer Research.